Clinical Trial Update: PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism [Phase 3]

View source ↗

Summary

Phase 3 PaTHway CHINA trial evaluating safety, tolerability, and efficacy of TransCon PTH in adults with hypoparathyroidism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism
• Parathyroid Hormone Deficiency

Drugs mentioned

• TransCon PTH (teriparatide)

Snippet

Sponsor: Visen Pharmaceuticals (Shanghai) Co., Ltd. | Conditions: Hypoparathyroidism, Parathyroid Hormone Deficiency | Phase 3 | Status: COMPLETED